SCHEMBL1121848

SCHEMBL1121848

Fc1ccc2c(CBr)nsc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
POLB P06746 1/20 0.36
MPI P34949 2/20 0.33
GFER P55789 2/20 0.33
AXL P30530 1/20 0.33
BCKDK O14874 1/20 0.32
GRM4 Q14833 3/20 0.32
HTR1A P08908 2/20 0.31
DRD2 P14416 2/20 0.31
HTR2A P28223 2/20 0.31
G6PD P11413 1/20 0.31
PHOSPHO1 Q8TCT1 1/20 0.31
CCNB2 O95067 1/20 0.31
CDK1 P06493 1/20 0.31
CCNB1 P14635 1/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
CCNA1 P78396 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28760382 0.86 ALDH1A1 (0.34) ALDH1A1LMNAMAPTPOLBMPI
SCHEMBL8554627 0.78 CYP11B1 (0.35) ALDH1A1LMNAMAPTPOLBMPI
SCHEMBL8124099 0.72 BCKDK (0.45) ALDH1A1LMNAMAPTPOLBMPI
SCHEMBL1121782 0.72 CCNB2 (0.44) ALDH1A1LMNAMAPTPOLBMPI
SCHEMBL30487367 0.72 ALDH1A1 (0.53) ALDH1A1LMNAMAPTPOLBMPI
SCHEMBL8558730 0.69 HTR1A (0.35) ALDH1A1LMNAMAPTPOLBGRM4
SCHEMBL24898062 0.68
SCHEMBL24848632 0.68 ALDH1A1 (0.36) ALDH1A1LMNAMAPTPOLBMPI
SCHEMBL24898412 0.67 BCKDK (0.47) ALDH1A1LMNAMAPTPOLBMPI
SCHEMBL30211547 0.67 BCKDK (0.47) ALDH1A1LMNAMAPTPOLBMPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685100-B1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME (GB) 2011-02-09 EP disclosed
US-7094777-B2 5-HT2A receptor ligands MERK SHARP & DOHME LTD. 2006-08-22 US disclosed
EP-1685100-A1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS Merck Sharp & Dohme Limited (GB) 2006-08-02 EP disclosed
WO-2005030705-A9 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2006-04-20 WO disclosed
WO-2005047247-A1 NOVEL1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed
WO-2005047246-A1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DEIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed
US-20050101586-A1 Novel 5-HT2A receptor ligands MERCK SHARP & DOHME LTD. (GB) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101586-A1 Novel 5-HT2A receptor ligands HTR2A, HTR1A, HTR5A ALDH1A1 911/4885LMNA 3065/4885MAPT 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.